A recent 48-week randomized trial by Lifespan.io explored rapamycin's impact on aging. The study found that women experienced significant lean mass improvements and reduced pain compared to men. These results suggest that controlled low-dose rapamycin could influence healthspan, warranting further investigation in longevity research.